Brian Elsbernd - Dec 27, 2023 Form 4 Insider Report for CATALYST PHARMACEUTICALS, INC. (CPRX)

Role
Chief Compliance/Legal Officer
Signature
/s/ Brian Elsbernd
Stock symbol
CPRX
Transactions as of
Dec 27, 2023
Transactions value $
$0
Form type
4
Date filed
12/29/2023, 05:00 PM
Previous filing
Dec 12, 2023
Next filing
Feb 16, 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CPRX Common Stock, par value $0.001 per share Options Exercise +6.67K +4.83% 145K Dec 27, 2023 Direct F1
transaction CPRX Common Stock, par value $0.001 per share Tax liability -2.62K -1.81% 142K Dec 27, 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CPRX Restricted Stock Units Options Exercise $0 -6.67K -0.65% $0.00 1.02M Dec 27, 2023 Common Stock 6.67K Direct F1, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting.
F2 Shares withheld by the Registrant to satisfy applicable withholding taxes upon vesting of restricted stock units.
F3 Derivative securities vest in equal tranches, 1/3rd on December 27, 2023, 1/3rd on December 27, 2024 and 1/3rd on December 27, 2025.
F4 Shares of common stock are required to be delivered to the Reporting Person within sixty days of vesting. The first tranche of shares was delivered on December 27, 2023.